Data from SIRT2 Regulates the SMARCB1 Loss-Driven Differentiation Block in ATRT
作者:Irina Alimova, Dong Wang, John DeSisto, Etienne Danis, Senthilnath Lakshmanachetty, Eric Prince, Gillian Murdock, Angela Pierce, Andrew M. Donson, Ilango Balakrishnan, Natalie J. Serkova, Hening Lin, Nicholas K. Foreman, Nathan Dahl, Sujatha Venkataraman, Rajeev Vibhakar · 年份:2025 · DOI:10.1158/1541-7786.c.7854101 · 被引用次数:1 · 研究领域:RNA regulation and disease、Cancer Mechanisms and Therapy、Chromatin Remodeling and Cancer
<div>Abstract<p>An atypical teratoid rhabdoid tumor (ATRT) is a highly aggressive pediatric brain tumor driven by the loss of<i> SMARCB1</i>, which results in epigenetic dysregulation of the genome. <i>SMARCB1</i> loss affects lineage commitment and differentiation by controlling gene expression. We hypothesized that additional epigenetic factors cooperate with <i>SMARCB1</i> loss to control cell self-renewal and drive ATRT. We performed an unbiased epigenome-targeted screen to identify genes that cooperate with <i>SMARCB1</i> and identified <i>SIRT2</i> as a key regulator. Using <i>in vitro</i> pluripotency assays combined with <i>in vivo</i> single-cell RNA transcriptomics, we examined the impact of <i>SIRT2</i> on differentiation of ATRT cells. We used a series of orthotopic murine models treated with <i>SIRT2</i> inhibitors to examine the impact on survival and clinical applicability. We found that ATRT cells are highly dependent on <i>SIRT2</i> for survival. Genetic or chemical inhibition led to decreased cell self-renewal and induction of differentiation in tumor spheres and <i>in vivo</i> models. We found that<i> SIRT2 </i>inhibition can restore gene expression programs lost because of <i>SMARCB1</i> loss and reverse the differentiation block in ATRT <i>in vivo</i>. Finally, we showed the <...